Colfax Corporation Stock News

Enovis remains out of favor despite solid results, but I still see potential for mid-single-digit revenue growth and low double-digit FCF margins long-term. The Recon business is performing well, gaining share in extremities, while P&R remains a slow-growth drag on overall performance and valuation. Tariff risks are manageable, but I'm unimpressed by the new CEO's lack of ortho experience.

Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Enovis Corporation (NYSE:ENOV ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Damien McDonald - CEO & Director Kyle William Rose - Vice President of Investor Relations Phillip Benjamin Berry - Senior VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Dane M. Reinhardt - Robert W.

Enovis (ENOV) Q2 Revenue Rises 7%

Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.

Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and Enovis DJO, LLC's DonJoy ROAM knee brace. The knee braces segment holds over 35% market share, fueled by prevalent knee injuries. Hinged braces show the highest growth at 5.31%. Key developments include Icarus Medical Innovation's Adonis Knee brace with joint-distraction technology and E...